Vertex Pharmaceuticals and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.
Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.
Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.
Vertex Pharmaceuticals will acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.
The online publication NEO.LIFE pointed to seven areas where biotech companies and researchers have significant potential to “dramatically reshape our concept of what it means to be human.”
Researchers at UC San Francisco recently published research in the journal Science describing their use of a modified version of CRISPR gene editing to stimulate the activity of certain genes, resulting in the prevention of severe obesity in mice who had a genetic predisposition to extreme weight gain.
The U.S. Food and Drug Administration lifted a clinical hold and accepted an Investigational New Drug Application (IND) for an experimental sickle cell disease treatment being jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 found it can cause unexpected genetic damage which could lead to dangerous changes in some cells.
Tmunity Therapeutics closed on a Series A financing worth $100 million. Syndicate investors included Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, and Be The Match BioTherapies.
The Broad Institute – a biological and genomic research center affiliated with MIT and Harvard – will keep valuable patents on a revolutionary gene-editing technology known as CRISPR, a U.S. patent agency ruled.